ImmunoCellular Therapeutics Exploding Higher on Clinical Data

Small-cap biotech firm ImmunoCellular Therapeutics

announced this morning that it will be presenting new data from its previously completed Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL. The clinical data supports the long-term efficacy of ICT-107 as 38% of patients were progression-free after four years. This news has put a charge into IMUC shares which were last trading up nearly 14% on much heavier than normal volume.